Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sandoz Group Ltd ( (CH:SDZ) ) has issued an update.
Sandoz reported strong full-year 2025 results, with net sales rising 7% in USD to USD 11.1 billion, driven by 15% biosimilar growth and an 8% increase in volumes, while core EBITDA margin expanded 160 basis points to 21.7% and core EPS jumped 34%. The company proposed a higher dividend, guided to mid-to-high single-digit net sales growth and further margin expansion in 2026, supported by a wave of biosimilar and generic launches, strategic acquisitions and licensing deals that deepen its oncology and retinal portfolios, even as pricing pressure in penicillin APIs and tariff-driven trade distortions weigh on its generics business into 2026.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF75.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz Group AG is a global leader in affordable medicines, focusing on generics and biosimilars that expand patient access to cost-effective treatments. The company targets high-growth therapeutic areas such as oncology, immunology, and chronic inflammatory and retinal diseases, and is building a vertically integrated European biosimilar development and manufacturing network.
Average Trading Volume: 713,670
Technical Sentiment Signal: Buy
Current Market Cap: CHF28.88B
For an in-depth examination of SDZ stock, go to TipRanks’ Overview page.